Bovine Mastitis Market, By Type (Clinical and Sub-Clinical), By Product (Antibiotics and Others), By Route of Administration (Intramammary and Systemic), By Therapy (Lactating Period and Dry Period (Antibiotics and Others)), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) – Global Forecast till 2029

Bovine mastitis, a medical disorder, usually affects the dairy cattle. In this disorder, the  inflammation of udder tissue and mammary gland can be seen. It can also lead to damage of  tissues secreting milk in the cattle; a basic reason why it is assumed to be a serious disorder. According to the Cornell University College of Veterinary Medicine, the global incidence is found to be between 0 and 200 for each 100 cows in bovine mastitis. Additionally, the University of Glasgow states that bovine mastitis will cost around $19.7 billion to $30 billion in healthcare burden every year. Additionally, the increase in the number of mastitis infection during dry period and the growing advantages of different intramammary non-antibiotic products such as teat sealants in prevention of new intramammary infection during the dry period are playing crucial role in boosting the overall market growth. Bovine Mastitis Market technologies market accounted for US$ 1.3 billion in 2020 and is estimated to be US$ 2.1 billion by 2029 and is anticipated to register a CAGR of 5.3%.

COVID-19 Impact on the Market:

With the outbreak of the COVID-19, various businesses are at the forefront to combat this pandemic. The pandemic has hindered the industrial supply chain and also disrupted the production segment. Government across the countries has imposed strict lockdown to limit the spread of disease. However, increasing investments by prominent players and other industries has created growth opportunities, during this chaotic situation, to fulfil the demand of suppliers. This report will measure the impact of this pandemic on the global bovine mastitis market.

Introduction:

Bovine mastitis, a medical disorder, usually affects the dairy cattle. In this disorder, the  inflammation of udder tissue and mammary gland can be seen. It can also lead to damage of  tissues secreting milk in the cattle; a basic reason why it is assumed to be a serious disorder. According to the Cornell University College of Veterinary Medicine, the global incidence is found to be between 0 and 200 for each 100 cows in bovine mastitis. Additionally, the University of Glasgow states that bovine mastitis will cost around $19.7 billion to $30 billion in healthcare burden every year. Additionally, the increase in the number of mastitis infection during dry period and the growing advantages of different intramammary non-antibiotic products such as teat sealants in prevention of new intramammary infection during the dry period are playing crucial role in boosting the overall market growth. The global bovine mastitis market technologies market accounted for US$ 1.3 billion in 2020 and is estimated to be US$ 2.1 billion by 2029 and is anticipated to register a CAGR of 5.3%.

COVID-19 Impact on the Market:

With the outbreak of the COVID-19, various businesses are at the forefront to combat this pandemic. The pandemic has hindered the industrial supply chain and also disrupted the production segment. Government across the countries has imposed strict lockdown to limit the spread of disease. However, increasing investments by prominent players and other industries has created growth opportunities, during this chaotic situation, to fulfil the demand of suppliers. This report will measure the impact of this pandemic on the global bovine mastitis market.

Bovine mastitis has become one of the serious concerns in the dairy industries across the globe. The dairy farmers are facing high monetary losses with the rise in the incidence of this cases in cattle every year. For instance, according to the research article published by the Journal of Dairy Science in 2017, 31 cases of clinical mastitis were reported in 100 cows per year in U.S. dairy herds. The cost was around USD 350 to USD 500 per case. This includes direct and indirect costs such as diagnostics, milk loss, veterinary services, labor, future milk production losses, and therapeutics, among others. The direct losses due to clinical mastitis are lower, as compared to indirect losses. Also, according to various regional and national estimates, an estimated 10% - 12% of total cost of mastitis per case, is associated with therapeutics. The rise in the incidence of the disease among bovine animals and growing awareness among dairy farmers regarding treatment is fuelling the demand for antibiotics in treatment of the condition. This is further augmented by the introduction of non-antibiotic drugs by market players, for bovine mastitis treatment.

Introduction of New Products for the Treatment to Provide Lucrative Growth to the Market

Novel developments are anticipated to have a huge impact on this market. Many veterinary companies are currently emphasizing on the launch of new products. Market players are entering into strategic mergers, partnerships, and acquisitions to leverage a synergistic effect, and accelerate the development of new products to prevent the increasing incidence of mastitis. For instance, in February 2020, Merck & Co., Inc. announced the launch of Shut Out, a new teat sealant which is an antibiotic-free intramammary paste, specifically intended to aid in the prevention of intramammary infections including mastitis in cattle. These new product introductions are anticipated to fill the clinical gap currently posed by the antibiotics, and other drugs for efficient treatment of mastitis.

However, technical and clinical-related challenges might hamper the growth of the global market to a certain extent.

Global bovine mastitis market is segments based upon the product, route of administration, therapy, and region.

Depending upon the type, global bovine mastitis market is categorized into Clinical, and Sub-Clinical. Depending upon the Product, global market is categorized into Antibiotics, and Others. Depending upon the Route of Administration, the target market is categorized into Intramammary, and Systemic.  Depending upon the Therapy, target market is categorized into Lactating Period and Dry Period, Further Dry period is categorised into Antibiotics and Others. Regionally, the overall industry is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America Bovine Mastitis Market held a dominant position in 2019. In terms of value, it was followed by Europe. Asia Pacific is expected to witness positive growth owing to increased governmental funding for research in life science sector, increasing demand for products and rising presence of companies in the region.

• Report Scope:

Segments Covered in the Report:

This report predication revenue growth at global, regional, country levels and serves the analysis of the recent trends and opportunities in each of the sub-segments from 2020 to 2027.  For this study, has segmented the global proteinase K market report based on type, physical form, application, end-user, and region.

Based on Type:

• Clinical, and
• Sub-Clinical.

Based on Product Type: 

• Antibiotics,
• and Others

Based on the Route of Administration:

• Intramammary,
• Systemic

Based on the Therapy:

• Lactating Period and
• Dry Period (Antibiotics and Others)

Global Bovine Mastitis Market, By Region:

• • • North America
      • • The U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in global bovine mastitis market include Zoetis, Merck & Co., Inc. (MSD Animal Health), Boehringer Ingelheim International GmbH, Bayer AG, Elanco, Ceva, West Way Health. Key players are undertaking various strategies to expand their market presence. For instance, Elanco announced the agreement to acquire Bayer’s Animal Health Business, which will together provide both the companies a strong platform for the development of novel treatments for bovine mastitis.

• Zoetis
• Merck & Co., Inc. (MSD Animal Health)
• Boehringer Ingelheim International GmbH
• Bayer AG
• Elanco
• Ceva
• West Way Health